P
P

Pfizer


Notícias

New York Times business news - Sept 24

Sept 24 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - The director of the Centers for Disease Control and Prevention on Friday overruled a recommendation by an agency advisory panel that had refused to endorse booster shots of the P
P

Australia shares slip as gold, metal stocks drag

Sept 24 (Reuters) - Australian shares fell on Friday, dragged by heavyweight gold and metal stocks on weaker bullion and copper prices overnight, while gains in energy stocks and banks limited the losses. The benchmark S&P/ASX 200 index .AXJO fell 0.21% to 7,354.9 points as at 0137 GMT and headed for its third weekly loss. Gold prices fell about 1%
A
N
P
Q
W
B
J

New York Times business news - Sept 23

Sept 23 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - After weeks of internal strife at the U.S. Food and Drug Administration, the agency on Wednesday authorized people over 65 who had received Pfizer-BioNTech's COVID-19 vaccine to
A
P

Wall Street Journal - Sept 23

Sept 23 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - U.S. health authorities cleared COVID-19 vaccine booster shots for people 65 and older and certain other adults at high risk of severe illness, a bid to help curb the pandemic and the dang
A
F
P
U

Canada - Sept. 21

Sept 21 (Reuters) - The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy. THE GLOBE AND MAIL ** Bank of Montreal Wealth Management head Joanna Rotenberg will replace Kathy Murphy as the head of Fidelity's US$4.1-trillion personal investing division at the e
P

Wall Street Journal - Sept 21

Sept 21 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - Coinbase Global Inc COIN.O won't offer a lending program that drew the threat of enforcement action from U.S. regulators. Link - Pfizer Inc PFE.N and partner BioNTech SE 22UAy.DE said thei
P

Regulators could OK Pfizer boosters for older Americans this week

By Michael Erman Sept 20 (Reuters) - U.S. regulators could authorize a booster shot of the Pfizer Inc PFE.N /BioNTech SE BNTX.O COVID-19 vaccine for older and some high-risk Americans early this week in time for the government to roll them out by Friday. The Food and Drug Administration is expected to give the nod to the third shots for at least th
P

Pfizer/BioNTech say data show 19 vaccine safe and protective in kids

By Michael Erman Sept 20 (Reuters) - Pfizer Inc PFE.N and BioNTech SE BNTX.O said on Monday their COVID-19 vaccine induced a robust immune response in 5 to 11 year olds, and they plan to ask for regulatory authorization as soon as possible to use the shot in children in that age range in the United States, Europe and elsewhere. The companies said t
P

Thailand to try alternative 19 vaccination method to stretch supplies

By Panarat Thepgumpanat and Chayut Setboonsarng BANGKOK, Sept 20 (Reuters) - Doctors in Thailand have been given the go-ahead to start giving COVID-19 booster shots under the skin, rather than injecting them into muscles, officials said on Monday, in an effort to strengthen immunity and stretch vaccine supplies. Health Minister Anutin Charnvirakul
A
P

Pfizer/BioNTech say data show 19 vaccine safe and protective in kids

By Michael Erman Sept 20 (Reuters) - Pfizer Inc PFE.N and BioNTech SE BNTX.O said on Monday their COVID-19 vaccine induced a robust immune response in 5 to 11 year olds, and they plan to ask for authorization to use the vaccine in children in that age range in the United States, Europe and elsewhere as soon as possible. The companies said the vacci
P

Regulators expected to OK Pfizer boosters for older Americans this week

By Michael Erman Sept 20 (Reuters) - U.S. regulators are expected to authorize a third booster shot of the Pfizer Inc PFE.N /BioNTech SE BNTX.O COVID-19 vaccine for older and some high-risk Americans early this week in time for the government to roll them out by Friday as hoped. The Food and Drug Administration is expected to give the nod to the sh
P

Here's what you need to know about the coronavirus right now

Sept 20 (Reuters) - Here's what you need to know about the coronavirus right now: Pfizer, BioNTech say data show vaccine safe in kids Pfizer and BioNTech said on Monday their COVID-19 vaccine induced a robust immune response in 5-to-11 year-olds, and they plan to seek authorisation to use the vaccine in children in that age range in Europe, the Uni
P

Wall Street closes rollercoaster week sharply lower

(For a live blog on the U.S. stock market, click or type LIVE/ in a news window.) * Nasdaq leads losses as technology majors sink * S&P 500 ends below 50-day moving average * Triple options expiry causes late session volume spike * Indexes post weekly losses * Indexes down: Dow 0.48%, S&P 0.91%, Nasdaq 0.91% (Updates with closing prices) By Stephen
P
U
U

Wall Street ends rollercoaster week sharply lower

(For a live blog on the U.S. stock market, click or type LIVE/ in a news window.) (Updates to market close) By Stephen Culp NEW YORK, Sept 17 (Reuters) - U.S. stocks closed sharply lower in a broad sell-off on Friday, ending a week buffeted by strong economic data, corporate tax hike worries, the Delta COVID variant, and possible shifts in the U.S.
P
U
U

Wall Street slides, ending seesaw week in a risk-off mood

(For a live blog on the U.S. stock market, click or type LIVE/ in a news window.) * Nasdaq leads losses as technology majors sink * S&P 500 trades close to 50-day moving average * Triple options expiry likely to increase volatility * Indexes set for weekly losses * Indexes down: Dow 0.49%, S&P 0.87%, Nasdaq 1.05% By Stephen Culp NEW YORK, Sept 17 (
P
U
U

Sri Lankan shares log second straight weekly loss; nationwide curfew extended

Sept 17 (Reuters) - Sri Lankan shares clocked their second consecutive weekly loss as the island nation further extended its lockdown until Oct. 1 to tackle an upsurge in coronavirus cases. * The country's President Gotabaya Rajapaksa on Friday advised the health sector to administer Pfizer Inc's PFE.N COVID-19 vaccine to children between the ages
P

Hong Kong panel advises single dose of BioNTech COVID shot for teens

By Farah Master HONG KONG, Sept 16 (Reuters) - A panel of health experts advising the Hong Kong government has recommended children aged 12-17 should get only one dose of BioNTech's 22UAy.DE COVID-19 vaccine after reports of heart inflammation as a side effect. Professor Lau Yu-lung, who chairs the health committee advising the government on its va
P

New York Times business news - Sept 16

Sept 16 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - The Food and Drug Administration offered the first public look at Pfizer Inc's PFE.N application for a booster coronavirus shot, two days before an outside advisory committee of
P

Hong Kong panel recommends single dose of BioNTech's 19 shot for teenagers

HONG KONG, Sept 16 (Reuters) - A panel of health experts advising the Hong Kong government has recommended children aged 12-17 should get only one dose of BioNTech's 22UAy.DE COVID-19 vaccine after reports of heart inflammation side effects. Professor Lau Yu-lung, who chairs a health committee advising the government on its vaccination programme, t
P

UK plans COVID boosters for over 50s to cope with "bumpy" winter

* Booster shot recommended for all Britons over 50 * Third shot also eyed for vulnerable and some health staff * Johnson hopes "Plan B" can avoid economically damaging lockdowns * Winter could be bumpy at times, health official says By Alistair Smout LONDON, Sept 14 (Reuters) - Britain will begin a COVID-19 vaccine booster programme for older and m
P



Condições

Ativos populares

Isenção de Responsabilidade: As entidades do XM Group proporcionam serviço de apenas-execução e acesso à nossa plataforma online de negociação, permitindo a visualização e/ou uso do conteúdo disponível no website ou através deste, o que não se destina a alterar ou a expandir o supracitado. Tal acesso e uso estão sempre sujeitos a: (i) Termos e Condições; (ii) Avisos de Risco; e (iii) Termos de Responsabilidade. Este, é desta forma, fornecido como informação generalizada. Particularmente, por favor esteja ciente que os conteúdos da nossa plataforma online de negociação não constituem solicitação ou oferta para iniciar qualquer transação nos mercados financeiros. Negociar em qualquer mercado financeiro envolve um nível de risco significativo de perda do capital.

Todo o material publicado na nossa plataforma de negociação online tem apenas objetivos educacionais/informativos e não contém — e não deve ser considerado conter — conselhos e recomendações financeiras, de negociação ou fiscalidade de investimentos, registo de preços de negociação, oferta e solicitação de transação em qualquer instrumento financeiro ou promoção financeira não solicitada direcionadas a si.

Qual conteúdo obtido por uma terceira parte, assim como o conteúdo preparado pela XM, tais como, opiniões, pesquisa, análises, preços, outra informação ou links para websites de terceiras partes contidos neste website são prestados "no estado em que se encontram", como um comentário de mercado generalizado e não constitui conselho de investimento. Na medida em que qualquer conteúdo é construído como pesquisa de investimento, deve considerar e aceitar que este não tem como objetivo e nem foi preparado de acordo com os requisitos legais concebidos para promover a independência da pesquisa de investimento, desta forma, deve ser considerado material de marketing sob as leis e regulações relevantes. Por favor, certifique-se que leu e compreendeu a nossa Notificação sobre Pesquisa de Investimento não-independente e o Aviso de Risco, relativos à informação supracitada, os quais podem ser acedidos aqui.

Usamos cookies para lhe dar a melhor experiência no nosso website. Ler mais ou alterar as configurações de cookies.

Aviso de risco: O seu capital está em risco. Os produtos alavancados podem não ser adequados para todos. Recomendamos que consulte a nossa Divulgação de Riscos.